Cases & Deals

  • Home
  • Practices
  • Resonant Therapeutics enters into target discovery and therapeutic validation collaboration agreement with Janssen

Share

Resonant Therapeutics enters into target discovery and therapeutic validation collaboration agreement with Janssen

January 2020

Client(s) Resonant Therapeutics, Inc.

Jones Day represented Resonant Therapeutics, Inc. in an agreement with Janssen Research and Development, LLC with the aim to discover and validate novel tumor and immunological targets and to validate certain therapeutic candidates. The collaboration leverages Resonant's proprietary IMPaCT tumor microenvironment model and target validation platform, and Janssen's industry-leading oncology capabilities to rapidly advance new targets and therapeutic opportunities.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.